aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $20.20 Average Target Price from Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) have been assigned a consensus rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $20.20.

A number of research firms recently weighed in on ATYR. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company raised their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, June 20th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Octagon Capital Advisors LP boosted its holdings in shares of aTyr Pharma by 294.7% in the 1st quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after buying an additional 2,652,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of aTyr Pharma by 46.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company's stock valued at $1,155,000 after buying an additional 120,496 shares during the period. Millennium Management LLC boosted its holdings in shares of aTyr Pharma by 334.5% in the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after buying an additional 1,231,052 shares during the period. Ally Bridge Group NY LLC boosted its holdings in shares of aTyr Pharma by 11.0% in the 1st quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock valued at $2,347,000 after buying an additional 77,290 shares during the period. Finally, MAI Capital Management boosted its holdings in shares of aTyr Pharma by 306,100.0% in the 1st quarter. MAI Capital Management now owns 658,330 shares of the company's stock valued at $1,988,000 after buying an additional 658,115 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Stock Up 3.9%

ATYR traded up $0.20 during trading hours on Monday, reaching $5.31. 2,883,236 shares of the stock traded hands, compared to its average volume of 1,116,948. The firm's fifty day simple moving average is $4.12 and its two-hundred day simple moving average is $3.70. The company has a market cap of $472.59 million, a price-to-earnings ratio of -6.56 and a beta of 0.88. aTyr Pharma has a fifty-two week low of $1.47 and a fifty-two week high of $5.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. As a group, analysts forecast that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.